Cannabidiol (CBD) is known for its anti-inflammatory and for its non-psychoactive properties. Research has shown that this compound interacts with extra-cannabinoid system receptor sites, like the peroxisome proliferator-activated receptor-gamma (PPARG) also known as the glitazone receptor. These receptors are found in adipose tissue, colon and macrophages. PPARG regulates fatty acid storage and glucose metabolism. CBD also controls reactive gliosis in the neuroimmune axis (CNS) which helps to reduce inflammation in the intestines due to Ulcerative Colitis (UC) and reduces damage to the intestines mediated by PPARG pathway. Patients with Irritable Bowel Syndrome (IBS) are also benefited by these interactions.
All this is good news for consumers who are looking for medicines with no or low toxicity, no “head high”, and is safe to give to children without all the unnecessary side effects.